Roche 9-Month Sales Rise 6% at CER to 46.5 Billion Francs, Confirms 2026 Outlook

Roche (RO.SW, ROG.SW) reported sales of 46.5 billion francs for the first nine months of 2026, up 6% at constant exchange rates and 1% in Swiss francs, citing strong demand for pharmaceuticals and diagnostics. The company confirmed its full-year outlook. The Pharmaceuticals Division posted sales of 36.2 billion francs, up 7% at CER and 2% in Swiss francs. The top five growth drivers — Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo — generated 16.8 billion francs, a 12% increase at CER and 6% in Swiss francs versus the same period of 2025. CEO Thomas Schinecker said third-quarter sales grew 7% at CER and 8% in Swiss francs. Roche targets mid single-digit Group sales growth for 2026, high single-digit growth in core earnings per share, and a further dividend increase in Swiss francs. Shares closed at 392.00 francs on the SIX Swiss Exchange.